UBS Group AG cut its stake in Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) by 80.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,275 shares of the biopharmaceutical company’s stock after selling 35,142 shares during the period. UBS Group AG owned 0.16% of Bellicum Pharmaceuticals worth $39,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. purchased a new position in Bellicum Pharmaceuticals during the 4th quarter worth approximately $197,000. Principal Financial Group Inc. increased its holdings in Bellicum Pharmaceuticals by 38.7% in the 4th quarter. Principal Financial Group Inc. now owns 503,151 shares of the biopharmaceutical company’s stock worth $649,000 after acquiring an additional 140,494 shares in the last quarter. Geode Capital Management LLC boosted its stake in Bellicum Pharmaceuticals by 18.1% during the 4th quarter. Geode Capital Management LLC now owns 416,449 shares of the biopharmaceutical company’s stock worth $537,000 after purchasing an additional 63,864 shares during the last quarter. Oxford Asset Management LLP boosted its stake in Bellicum Pharmaceuticals by 18.9% during the 4th quarter. Oxford Asset Management LLP now owns 352,465 shares of the biopharmaceutical company’s stock worth $455,000 after purchasing an additional 56,116 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC boosted its stake in Bellicum Pharmaceuticals by 175.2% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 31,415 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 20,000 shares during the last quarter. Institutional investors own 30.12% of the company’s stock.
NASDAQ BLCM opened at $7.54 on Wednesday. The firm’s 50-day moving average is $7.79 and its two-hundred day moving average is $5.46. Bellicum Pharmaceuticals Inc has a 12 month low of $3.32 and a 12 month high of $27.90. The company has a debt-to-equity ratio of 28.20, a current ratio of 1.60 and a quick ratio of 1.60. The stock has a market capitalization of $38.08 million, a P/E ratio of -0.44 and a beta of 2.17.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($2.73) by $3.82. Bellicum Pharmaceuticals had a negative net margin of 1,574.65% and a negative return on equity of 664.19%. As a group, analysts anticipate that Bellicum Pharmaceuticals Inc will post -9.32 EPS for the current year.
BLCM has been the topic of several recent research reports. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.00 price target on the stock in a research report on Wednesday, May 13th. ValuEngine raised shares of Bellicum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Finally, Raymond James decreased their target price on shares of Bellicum Pharmaceuticals from $40.00 to $17.00 and set an “outperform” rating on the stock in a research report on Friday, March 13th.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.
Featured Story: What is a Backdoor Roth IRA?
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.